Statement from Treatment Action Group on FDA priority peview of TB Alliance’s new anti-TB drug pretomanid.

Treatment Action Group (TAG), AVAC, the Elizabeth Glaser Pediatric AIDS Foundation, Health GAP, IMPAACT4TB, and RESULTS hosted a webinar on 23 January 2019 on how to strategize and engage in PEPFAR Country Operational Plans (COPs) planning to address and strengthen the global response to TB through PEPFAR, and introduced tools to galvanize advocacy efforts.

Back by popular demand! As tuberculosis (TB) is the leading global killer of people living with HIV, TB programming must be prioritized and integrated within life-saving bilateral efforts such as PEPFAR. The expected release of the PEPFAR Country Operational Plans (COPs) provides a critical opportunity for advocates to ensure that the latest developments in TB treatment, prevention and diagnostics are implemented within PEPFAR countries.

Bringing down the House on intellectual property and access

Global funding for TB research climbed to a previously unreported high of USD $772 million in 2017.

A new checklist from Treatment Action Group lays out simply the core elements of an adequate TB response.

The "Reality Check" dispels myths that have been circulated among members of the global TB community and used to justify pricing bedaquiline out of the reach of TB programs and patients.

The guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward.

The Global Coalition of TB Activists (GCTA), Treatment Action Group (TAG) and the DR-TB Scale-Up Treatment Action Team (DR-TB STAT) developed a letter template to help activists call for bedaquiline-based, injectable-free regimens for the treatment of drug-resistant TB in their countries.

A new brief from Treatment Action Group shows that global funding for TB research reached a new high of USD $767.8 million in 2017.